JP2017513897A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513897A5
JP2017513897A5 JP2016564122A JP2016564122A JP2017513897A5 JP 2017513897 A5 JP2017513897 A5 JP 2017513897A5 JP 2016564122 A JP2016564122 A JP 2016564122A JP 2016564122 A JP2016564122 A JP 2016564122A JP 2017513897 A5 JP2017513897 A5 JP 2017513897A5
Authority
JP
Japan
Prior art keywords
substituents
optionally substituted
optionally
heteroaryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016564122A
Other languages
English (en)
Japanese (ja)
Other versions
JP6762233B2 (ja
JP2017513897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2015/050330 external-priority patent/WO2015161373A1/en
Publication of JP2017513897A publication Critical patent/JP2017513897A/ja
Publication of JP2017513897A5 publication Critical patent/JP2017513897A5/ja
Application granted granted Critical
Publication of JP6762233B2 publication Critical patent/JP6762233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016564122A 2014-04-22 2015-04-21 化合物および造血幹細胞および/または造血前駆細胞の増大におけるその使用 Active JP6762233B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982445P 2014-04-22 2014-04-22
US61/982,445 2014-04-22
PCT/CA2015/050330 WO2015161373A1 (en) 2014-04-22 2015-04-21 Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells

Publications (3)

Publication Number Publication Date
JP2017513897A JP2017513897A (ja) 2017-06-01
JP2017513897A5 true JP2017513897A5 (https=) 2018-06-07
JP6762233B2 JP6762233B2 (ja) 2020-09-30

Family

ID=54331531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564122A Active JP6762233B2 (ja) 2014-04-22 2015-04-21 化合物および造血幹細胞および/または造血前駆細胞の増大におけるその使用

Country Status (7)

Country Link
US (1) US10647718B2 (https=)
EP (1) EP3134409B1 (https=)
JP (1) JP6762233B2 (https=)
CN (2) CN106414445B (https=)
CA (1) CA2946446C (https=)
ES (1) ES2788977T3 (https=)
WO (1) WO2015161373A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107208111B (zh) 2014-09-18 2021-07-06 蒙特利尔大学 用于增强病毒基因转移至人造血细胞的化合物和方法
CA3024273A1 (en) * 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
JP7018026B2 (ja) * 2016-06-16 2022-02-09 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
KR102522572B1 (ko) * 2016-08-18 2023-04-17 내셔널 유니버시티 오브 싱가포르 조혈 줄기 및 전구 세포의 생성, 증식 및 분화를 위한 치환된 아졸 유도체
CN106727541A (zh) * 2017-02-20 2017-05-31 刘金涛 一种治疗耳肿胀的药物组合物
CN107353288B (zh) * 2017-06-23 2019-10-18 吉林大学 4-乙胺(2-羧基)-9H-嘧啶并[4,5-b]吲哚及其制备方法
AU2018354418B2 (en) * 2017-10-27 2025-09-11 Immunebridge Inc. Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene
US12011460B2 (en) 2018-02-20 2024-06-18 Universite De Montreal Expansion of NK and DC cells in vivo mediating immune response
KR102329235B1 (ko) * 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
WO2020106059A1 (ko) * 2018-11-21 2020-05-28 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
AU2020409437A1 (en) * 2019-12-18 2022-07-14 Universite De Montreal Modulators of Cullin 3 adaptor KBTBD4 as anti-cancer compounds
MX2022008715A (es) * 2020-01-24 2022-07-21 Univ Tokyo Medio libre de suero y metodo de cultivo adecuado para el cultivo de celulas sanguineas, incluidas celulas madre hematopoyeticas humanas.
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
US11851430B1 (en) * 2023-09-06 2023-12-26 King Faisal University Pyrido[4,3-B]indole-7-carboxylic acid compounds as CK2 inhibitors
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
CN120157613A (zh) * 2023-12-15 2025-06-17 山东诚创蓝海医药科技有限公司 多拉韦林中间体及其应用和合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2595701B1 (fr) 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
JP2002529502A (ja) 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
EP1213965B1 (en) 1999-09-10 2006-01-18 Smithkline Beecham Corporation Thrombopoietin mimetics
ATE350044T1 (de) 1999-09-24 2007-01-15 Smithkline Beecham Corp Thrombopoietinmimetika
WO2001034585A1 (en) 1999-11-05 2001-05-17 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
AU2079901A (en) 1999-12-06 2001-06-12 Smithkline Beecham Corporation Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
WO2002049413A2 (en) 2000-12-19 2002-06-27 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1442039A1 (en) * 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
AU2003248630A1 (en) 2002-06-06 2003-12-22 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1581527A4 (en) 2002-12-13 2006-11-22 Smithkline Beecham Corp MIMETICS OF THROMBOPOIETINE
ATE478863T1 (de) 2005-07-14 2010-09-15 Irm Llc Heterotetracyclische verbindungen als tpo- mimetica
US7816542B2 (en) 2005-08-15 2010-10-19 Irm Llc Compounds and compositions as TPO mimetics
US8518964B2 (en) * 2005-11-22 2013-08-27 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
KR20090021217A (ko) 2006-06-14 2009-02-27 추가이 세이야쿠 가부시키가이샤 조혈 줄기세포 증가 촉진제
JP2008050355A (ja) * 2006-08-21 2008-03-06 Eisai R & D Management Co Ltd 造血幹細胞を増殖、分化および/または循環系内に動員させる医薬組成物および方法
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
JP2010525836A (ja) * 2007-05-04 2010-07-29 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト造血幹細胞のexvivo増殖
CA2707491A1 (en) 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CN101423517B (zh) * 2008-11-28 2011-09-14 浙江大学 γ-咔啉类衍生物及其制备方法和用途
JP2010193879A (ja) 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
US20120157500A1 (en) 2009-08-24 2012-06-21 Weikang Tao Jak inhibition blocks rna interference associated toxicities
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
US9198900B2 (en) 2011-11-10 2015-12-01 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment of peritoneal injury using JAK inhibitors
PT2807165T (pt) * 2012-01-27 2019-07-12 Univ Montreal Derivados de pirimido[4,5-b]indole e sua utilização na expansão de células estaminais hematopoiéticas
CN107011342A (zh) 2012-05-22 2017-08-04 伊莱利利公司 用于检测神经功能障碍的基于咔啉和咔唑的成像剂
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same

Similar Documents

Publication Publication Date Title
JP2017513897A5 (https=)
JP2015504902A5 (https=)
HRP20191189T1 (hr) Pirimido[4,5-b]indol derivati i njihova primjena u ekspanziji hematopoetskih matičnih stanica
Braza et al. Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance
Kindwall-Keller et al. Umbilical cord blood: The promise and the uncertainty
Williamson et al. Bedside filtration of blood products in the prevention of HLA alloimmunization--a prospective randomized study. Alloimmunisation Study Group
JP2017524025A5 (https=)
Bacigalupo et al. Haploidentical donor transplants for severe aplastic anemia
Leonard et al. Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?
JP2014518882A5 (https=)
Strocchio et al. Hematopoietic stem cell transplantation in thalassemia
Lee et al. Intra-osseous injection of donor mesenchymal stem cell (MSC) into the bone marrow in living donor kidney transplantation; a pilot study
Yamamoto Single cord blood transplantation in Japan; expanding the possibilities of CBT
CA2797921A1 (en) Novel iridium/rhodium anti-cancer compounds
JP2014504622A5 (https=)
HUE029247T2 (en) Benzimidazole Respiratory Syncytial Virus Inhibitors
JP2015504047A5 (https=)
JP2014500296A5 (https=)
TW201841916A (zh) 芳香烴受體拮抗劑及其用途
Stokes et al. Post‐transplant bendamustine reduces Gv HD while preserving GvL in experimental haploidentical bone marrow transplantation
Aljagthmi et al. Hematopoietic stem cells: Understanding the mechanisms to unleash the therapeutic potential of hematopoietic stem cell transplantation
Bastani et al. The quest for the holy grail: overcoming challenges in expanding human hematopoietic stem cells for clinical use
RU2013110877A (ru) Способ активации регуляторных т-клеток агонистами альфа-2в адренергических рецепторов
Rujkijyanont et al. Ex vivo activation of CD56+ immune cells that eradicate neuroblastoma
JP2021521262A5 (https=)